See more : Gencor Industries, Inc. (GENC) Income Statement Analysis – Financial Results
Complete financial analysis of Synlogic, Inc. (SYBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Synlogic, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vividthree Holdings Ltd. (OMK.SI) Income Statement Analysis – Financial Results
- ElringKlinger AG (ZIL2.DE) Income Statement Analysis – Financial Results
- Samyang Holdings Corporation (000075.KS) Income Statement Analysis – Financial Results
- Vindhya Telelinks Limited (VINDHYATEL.BO) Income Statement Analysis – Financial Results
- Titan Kogyo, Ltd. (4098.T) Income Statement Analysis – Financial Results
Synlogic, Inc. (SYBX)
About Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.37M | 1.18M | 1.75M | 545.00K | 2.22M | 2.52M | 2.44M | 444.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 5.67M | 0.00 | 0.00 | 0.00 | 14.90M | 0.00 | 159.00K | 54.00K | 0.00 | 0.00 | 0.00 | 37.00K |
| Gross Profit | 3.37M | -4.49M | 1.75M | 545.00K | 2.22M | -12.38M | 2.44M | 285.00K | -54.00K | 0.00 | 0.00 | 0.00 | -37.00K |
| Gross Profit Ratio | 100.00% | -380.42% | 100.00% | 100.00% | 100.00% | -491.15% | 100.00% | 64.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 43.97M | 52.04M | 47.13M | 47.47M | 41.91M | 38.03M | 30.34M | 13.93M | 18.95M | 10.55M | 4.39M | 2.74M | 980.00K |
| General & Administrative | 14.56M | 16.56M | 15.39M | 13.54M | 14.73M | 15.72M | 12.93M | 8.12M | 6.08M | 3.37M | 2.38M | 1.56M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.56M | 16.56M | 15.39M | 13.54M | 14.73M | 15.72M | 12.93M | 8.12M | 6.08M | 3.37M | 2.38M | 1.56M | 1.47M |
| Other Expenses | 0.00 | 7.00K | 204.00K | 1.29M | 3.04M | 2.80M | 447.00K | 4.57M | 0.00 | 0.00 | 339.00K | 0.00 | 0.00 |
| Operating Expenses | 58.53M | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M | 43.27M | 22.05M | 25.03M | 13.91M | 6.78M | 4.30M | 2.45M |
| Cost & Expenses | 58.53M | 68.60M | 62.52M | 61.01M | 56.63M | 53.75M | 43.27M | 22.05M | 25.03M | 13.91M | 6.78M | 4.30M | 2.48M |
| Interest Income | 2.47M | 1.27M | 210.00K | 1.30M | 3.06M | 2.84M | 504.00K | 350.00K | 44.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00K | 2.00K | 2.00K | 6.00K | 21.00K | 43.00K | 57.00K | 0.00 | 44.00K | 0.00 | 0.00 | 355.00K | 399.00K |
| Depreciation & Amortization | 1.96M | 3.79M | 2.44M | 2.64M | 2.70M | 2.42M | 2.31M | 692.00K | 54.00K | 35.00K | 36.00K | 37.00K | 37.00K |
| EBITDA | -55.16M | -63.63M | -58.12M | -57.83M | -47.28M | -45.97M | -38.01M | -24.70M | -24.93M | -15.80M | -6.74M | -3.27M | -2.45M |
| EBITDA Ratio | -1,636.34% | -5,391.95% | -3,464.37% | -11,094.68% | -2,446.45% | -2,032.94% | -1,670.38% | -3,936.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -55.16M | -67.42M | -60.77M | -60.47M | -54.41M | -51.23M | -40.82M | -26.62M | -25.03M | -15.83M | -6.78M | -4.30M | -2.48M |
| Operating Income Ratio | -1,636.34% | -5,713.47% | -3,464.37% | -11,094.68% | -2,446.45% | -2,032.94% | -1,670.38% | -5,995.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.11M | 1.27M | 204.00K | 1.29M | 3.04M | 2.80M | 447.00K | 10.00K | 44.00K | -1.92M | 339.00K | 646.00K | -399.00K |
| Income Before Tax | -57.27M | -66.15M | -60.56M | -59.17M | -51.37M | -48.44M | -40.38M | -26.27M | -24.98M | -15.83M | -6.44M | -3.66M | -2.88M |
| Income Before Tax Ratio | -1,698.84% | -5,605.68% | -3,452.74% | -10,857.43% | -2,309.94% | -1,922.02% | -1,652.09% | -5,916.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 14.00K | -1.27M | -2.44M | -2.64M | -2.70M | 2.84M | -2.31M | 4.06M | -54.00K | 0.00 | 0.00 | 355.00K | 0.00 |
| Net Income | -57.28M | -64.88M | -58.12M | -56.54M | -48.67M | -48.44M | -40.38M | -26.27M | -24.98M | -15.83M | -6.44M | -3.66M | -2.88M |
| Net Income Ratio | -1,699.26% | -5,497.88% | -3,313.45% | -10,373.76% | -2,188.44% | -1,922.02% | -1,652.09% | -5,916.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.81 | -13.57 | -15.76 | -23.67 | -24.11 | -30.42 | -90.07 | -8.83 | -34.90 | -13.98 | -5.68 | -4.52 | -20.96 |
| EPS Diluted | -8.81 | -13.57 | -15.76 | -23.67 | -24.11 | -30.42 | -90.07 | -8.83 | -34.90 | -13.98 | -5.68 | -4.52 | -20.96 |
| Weighted Avg Shares Out | 6.50M | 4.78M | 3.69M | 2.39M | 2.02M | 1.59M | 448.31K | 2.98M | 715.76K | 1.13M | 1.13M | 809.17K | 198.39K |
| Weighted Avg Shares Out (Dil) | 6.50M | 4.78M | 3.69M | 2.39M | 2.02M | 1.59M | 448.31K | 2.98M | 715.76K | 1.13M | 1.13M | 809.17K | 198.39K |
Synlogic Reports Third Quarter 2024 Financial Results
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update.
Synlogic Reports Second Quarter 2024 Financial Results
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update.
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
“Sell in May and go away” is a common adage in investing. It's based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines.
Synlogic Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Synlogic, Inc. (SYBX) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago.
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.
Synlogic Adopts Limited Duration Stockholders Rights Plan
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process
Why Is Synlogic (SYBX) Stock Down 55% Today?
Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release from Synlogic, this decision comes after an internal review of the clinical trial's progress.
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08,...
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study
Source: https://incomestatements.info
Category: Stock Reports